Express Scripts excludes Lilly's low cost insulin generic from preferred formulary

Express Scripts Holding Co. (NASDAQ:ESRX) excluded from its 2019 preferred formulary Eli Lilly's newly launched generic insulin product, reinforcing the idea that PBMs want bigger rebates, not cheaper drugs.

PBMs and

Read the full 305 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE